Gedatolisib - Pfizer

Drug Profile

Gedatolisib - Pfizer

Alternative Names: PF-05212384; PF-5212384; PKI-587

Latest Information Update: 12 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Wyeth
  • Developer Curie Institute; Eastchester Center for Cancer Care; Indiana University; Netherlands Cancer Institute; Pfizer; University of Florida
  • Class Antineoplastics; Morpholines; Piperidines; Small molecules; Triazines; Urea compounds
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase II Colorectal cancer; Non-small cell lung cancer
  • Phase I Breast cancer; Solid tumours
  • Discontinued Endometrial cancer

Most Recent Events

  • 08 Oct 2018 Korean Cancer Study Group plans a phase II trial for Breast Cancer (Late-stage disease, Second-line or greater therapy) in October 2018 , (NCT03698383)
  • 04 Oct 2018 Levine Cancer Institute, Atrium Health and Pfizer plan a clinical trial in Breast cancer (Early-stage disease) in USA
  • 04 Oct 2018 University of Wisconsin Carbone Cancer Center and Pfizer plan a phase II trial in triple negative or BRCA1 or 2 positive, HER2 negative Breast cancer (Combination therapy, Late-stage disease) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top